Personalized Cell Therapy

Tackling some of the greatest unmet needs

in healthcare
Investment Summary
Focused on executing pivotal clinical trials to market approval
targeting some of the greatest unmet needs in healthcare

Series A: Target Raise $40 million

• Execute (IDE) late-stage clinical trials

• Diabetic Foot Ulcer Pivotal US Prevalence: 7.5M 5% market = $2.25B
• Sclero Hand Dysf Pivotal US Prevalence: 300K 5% market = $90M
• Heart Failure Mid Stage US Prevalence: 6.2M 5% market = $2.8B
• DFU & Scleroderma approvals expected end of 2024, early 2025 respectively
• Clinical team includes leading experts in each specialty
• Data from completed trials reduces technology risks
• Thousands of patients treated globally – mitigates safety concerns
• Basic science, pre-clinical, engineering, product mfg, early/mid clinical - DONE
• 50+ devices & 600 consumables in inventory –ready to initiate clinical trials
2
 Easy 3-Step Process

1 2 3

Harvest small amount of fat Process tissue to cells Deliver back to patient

3
Business Model: Sell Single-Use Processing Cartridge (razor/blade)
Why Fat ?
Adipose is not only a reservoir of fats…
Largest Endocrine Organ
>600 proteins, hormones, peptides and cytokines
(“adipokines”)

Most active Immune Organ

(including All types of immune cells) Adipose Tissue

Adipokines regulate numerous biological functions

Inflammation
Immune system
Vascular function & hemostasis
Adipose tissue, Vascular and Nerve expansion / contraction
Energy homeostasis / appetite / satiety
Lipid & glucose metabolism
Learning & cognition
Reproduction & aging 4
 The Language of Healing

Adipose Derived Regenerative Cells

Endothelial Cells 7% Endothelial Cells
Smooth Muscle Cells 9%
Smooth Muscle Cells
Fibroblasts 38%
Mesenchymal Stem Cells 1-5% Perivascular Adipose Tissue

Blood Cells 22% Fibroblasts

Macrophages 23%

Blood Vessel

23% of ADRCs are Macrophages Cells, Adipokines & Cytokines

 Angiogenesis
 Anti-apoptosis
M1 MACROPHAGE M2 MACROPHAGE  Down regulate inflammation
Pro-inflammatory Anti-inflammatory
 Repair endothelial dysfunction
TNF-⍺, IL-6, IL-1β IL-10, IL-1Ra
• Produce  Recruit for healing vs scar
• Produce pro-inflammatory
cytokines immunosuppressive  Remodeling
• Minority of macrophages factors & anti-inflammatory  Source of Repair cells
in adipose cytokines
• Majority of macrophages
 Source of Immune cells
• Increases with obesity
in adipose  Source of T-Cells 5
Complex Disease Requires Dynamic Multi-modal Biologic Therapy
Vascular Therapy
 Perfusion
ADSCs  Vessel density
 VEGF, PlGF, bFGF
EPCs
 NOS,  ROS  Endothelial
Mø
dysfunction
Endo Pericyte differentiation
VSMCs & recruitment, Vessel stabilization
Pericytes SDF-1, PlGF & expansion

Immunotherapy
 Inflammation
ADSCs  IL-10,  IL-6  WBC recruitment
Mø & activation
 IL-1b,  TNF-⍺
T cells
 PGE2 Mø switch to M2

Regenerative Therapy
 Fibrosis  Repair
Mø  MMP1, TGFb,  Scar remodeling
EPCs  TIMP1  Recruitment of
Endo  SDF-1, IGF-1 stem cells
ADSCs  HGF, IGF-1  Apoptosis

Inflammatory Proliferative Remodeling 6

Injury – ~7 days ~Day 3 – ~Day 12+ ~Day 10 - weeks
Platform Enables Success to be Replicated
Stroke
Neurodegenerative Diseases
Macular Degeneration
Facial Volumizing, Aesthetics, Acne
Common Pathology Facial Wasting / Reconstruction
Breast Reconstruction
✗ Ischemia Lymphedema
Heart Attack
✗ Inflammation Heart Failure
Hypertension
M.S.
✗ Tissue Injury Raynaud’s
Burn / Scar Angina
COPD Diabetes
Wounds Renal Failure
Scleroderma Fistula / Crohn’s
Pulmonary Hypertension
Stress Urinary Incontinence
Erectile Dysfunction
Portal Hypertension
Peripheral Artery Disease
Chronic Liver Failure
Acute Kidney Injury
Bone Regeneration
Muscle Injury Repair
Tendon / Ligament Repair
Spinal Cord Injury / Disc Repair
Osteoarthritis
7
Neuropathy
Diabetic Foot Ulcers
Advanced Clinical Pipeline

Pre-Clinical Feasibility Study Pivotal Study Milestones

Q1 ’22 First pt In
Q4 ‘23 Last pt (PEP)
Q2 ‘24 File PMA
Q4’ 24 FDA Approval

Q2 ’22 First pt In
Q2 ‘24 Last pt (PEP)
Q3 ‘24 File PMA
Q1’ 25 FDA Approval

Q4 ’22 First pt In
TBD Last pt (PEP)
TBD File PMA

8
Global Mega Trend: OBESITY

75% of Americans are Overweight.

88% of Adults are Metabolically Unhealthy.
Mark Hyman, MD
Chairman, Institute for Functional Medicine

9
Competitive Advantages

Biologic Therapy Respond dynamically to local environmental signals by

releasing responsive signals back “Paracrine Effect”
Multimodal Heterogeneous population of cells provide multiple
clinically relevant mechanisms of action
3 in 1 Therapy 1. Restore blood flow
2. Reduce inflammation
3. Heal, repair and regenerate (damaged) tissue
One & Done One treatment in most indications
Autologous Patient’s Own Cells: Lowest risk, easy to harvest,
no rejection, multiple treatments
Device Based Fastest regulatory approach, fewer, smaller, less
expensive trials (approved in ~40 countries)
Point-of-care Real-time, single procedure, avoid expensive &
time consuming cell culturing
Affordable Cost of goods are in the hundreds of dollars,
end-user pricing is projected to be $6k – $9k
Competitor manufactured cell products: $50k - $400k
Banking Cryo-preserve for future use / multiple treatments 10